JGC
COLL icon

J. Goldman & Co’s Collegium Pharmaceutical COLL Stock Holding History

J. Goldman & Co’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-243,448
Closed -$7.2M – 479
2025
Q2 		$7.2M Buy
+243,448
New +$6.94M 0.17% 163
2021
Q3 		– Sell
-96,347
Closed -$2.28M – 362
2021
Q2 		$2.28M Buy
96,347
+19,790
+26% +$457K 0.09% 216
2021
Q1 		$1.81M Sell
76,557
-69,208
-47% -$1.64M 0.06% 249
2020
Q4 		$2.92M Buy
145,765
+76,401
+110% +$1.49M 0.15% 155
2020
Q3 		$1.44M Sell
69,364
-148,590
-68% -$2.68M 0.1% 188
2020
Q2 		$3.81M Sell
217,954
-156,588
-42% -$3.07M 0.24% 116
2020
Q1 		$6.12M Buy
374,542
+259,640
+226% +$5.36M 0.74% 31
2019
Q4 		$2.37M Sell
114,902
-20,297
-15% -$338K 0.17% 124
2019
Q3 		$1.55M Buy
135,199
+100,200
+286% +$1.14M 0.12% 166
2019
Q2 		$460K Sell
34,999
-200,016
-85% -$2.67M 0.03% 224
2019
Q1 		$3.56M Sell
235,015
-831,832
-78% -$13.3M 0.2% 131
2018
Q4 		$18.3M Sell
1,066,847
-515,038
-33% -$8.81M 1.41% 12
2018
Q3 		$23.3M Buy
1,581,885
+1,301,375
+464% +$23.1M 1.63% 13
2018
Q2 		$6.69M Buy
280,510
+56,486
+25% +$1.39M 0.35% 89
2018
Q1 		$5.72M Buy
+224,024
New +$5.34M 0.24% 113
2017
Q4 		– Sell
-522,593
Closed -$5.48M – 350
2017
Q3 		$5.48M Buy
522,593
+211,593
+68% +$2.33M 0.28% 104
2017
Q2 		$3.89M Sell
311,000
-33,129
-10% -$327K 0.21% 124
2017
Q1 		$3.46M Buy
344,129
+119,279
+53% +$1.77M 0.17% 166
2016
Q4 		$3.5M Buy
224,850
+146,850
+188% +$2.44M 0.23% 133
2016
Q3 		$1.5M Sell
78,000
-21,000
-21% -$249K 0.08% 210
2016
Q2 		$1.17M Buy
+99,000
New +$1.64M 0.06% 243

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

J. Goldman & Co's COLL Position: Q3 2025 in Review

J. Goldman & Co sold out of Collegium Pharmaceutical (COLL) in Q3 2025, closing a stake of 243,448 shares — an estimated $7.2M sold.

J. Goldman & Co first reported a position in COLL in Q2 2016 and held it in 21 quarters. The position peaked at $23.3M in Q3 2018. 244 funds tracked by Wall St. Rank hold COLL as of Q3 2025.

  • J. Goldman & Co reported no remaining Collegium Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 243,448 Collegium Pharmaceutical shares in Q3 2025, an estimated $7.2M.
  • J. Goldman & Co first reported a position in Collegium Pharmaceutical in Q2 2016 and held it in 21 quarters.
  • J. Goldman & Co's Collegium Pharmaceutical position peaked at $23.3M in Q3 2018.
  • 244 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.